1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Next-generation Antibody Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Next-generation Antibody Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Next-generation Antibody Market Regional Analysis
6.2 Europe Next-generation Antibody Market Revenue 2019-2028 (US$ Million)
6.3 Europe Next-generation Antibody Market Forecast Analysis
7. Europe Next-generation Antibody Market Analysis – by Therapeutic Area
7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Oncology: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Autoimmune or Inflammatory
- 7.2.1 Overview
- 7.2.2 Autoimmune or Inflammatory: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Europe Next-generation Antibody Market Analysis – by Technology
8.1 Antibody-drug conjugates
- 8.1.1 Overview
- 8.1.2 Antibody-drug conjugates: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Bispecific antibodies
- 8.2.1 Overview
- 8.2.2 Bispecific antibodies: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Fc engineered antibodies
- 8.3.1 Overview
- 8.3.2 Fc engineered antibodies: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.4 Antibody fragments & antibody-like proteins
- 8.4.1 Overview
- 8.4.2 Antibody fragments & antibody-like proteins: Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.5 Biosimilar antibody products
- 8.5.1 Overview
- 8.5.2 Biosimilar antibody products : Europe Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Europe Next-generation Antibody Market – Europe Analysis
9.1 Overview
9.2 Europe
- 9.2.1 Europe Next-generation Antibody Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 9.2.1.1 Europe Next-generation Antibody Market – Revenue and
Forecast Analysis – by Country
- 9.2.1.1 UK:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.1.1 UK: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.1.2 UK: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.2.1.2 Germany:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.2.1 Germany: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.2.2 Germany: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.2.1.3 France:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.3.1 France: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.3.2 France: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.2.1.4 Russia:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.4.1 Russia: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.4.2 Russia: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.2.1.5 Italy:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.5.1 Italy: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.5.2 Italy: Europe Next-generation Antibody Market Breakdown, by Technology
- 9.2.1.6 Rest of Europe:
Europe Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.6.1 Rest of Europe: Europe Next-generation Antibody Market Breakdown, by Therapeutic Area
- 9.2.1.6.2 Rest of Europe: Europe Next-generation Antibody Market Breakdown, by Technology
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Seagen Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Takeda Pharmaceutical Company Limited
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Amgen Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AstraZeneca
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
Get Free Sample For Europe Next-generation Antibody Market
